Anti-citrullinated peptide antibodies in lupus patients with or without deforming arthropathy

Abstract

The objective was to study the association of antibodies against cyclic citrullinated peptides (anti-CCP) in patients with lupus articular damage. We studied 34 systemic lupus erythematosus patients (30 women) with (n = 14) or without (n = 20) deforming arthropathy. Anti-DNA and arthritis were mandatory inclusion criteria for both groups. As controls, 34 patients with rheumatoid arthritis and nine patients with rheumatoid arthritis and systemic lupus erythematosus (rhupus) were included. Anti-CCP and rheumatoid factor were determined by ELISA and nephelometry respectively. All patients had recent x-ray films of the hands that were evaluated according to Sharp’s method. Systemic lupus erythematosus patients had a mean 6.50 ± 0.86 (SD, range 5–8) American College of Rheumatology (ACR) criteria, rheumatoid arthritis patients met 5.38 ± 0.60 (range 4–6) ACR criteria for rheumatoid arthritis and rhupus patients had 5.78 ± 0.44 (range 5–6) criteria for rheumatoid arthritis and 5.11 ± 0.78 (range 4–6) for systemic lupus erythematosus. Systemic lupus erythematosus patients, with or without deforming arthropathy, had normal serum anti-CCP concentrations. In contrast, rheumatoid arthritis and rhupus patients had 30- and 23-fold higher than normal amounts of anti-CCP (p < 0.001, both comparisons). Rheumatoid arthritis (97%) and rhupus (100%) patients were more frequently positive for anti-CCP than SLE patients with (7%) or without (5%) deforming arthropathy (p < 0.001, both comparisons). Patients with lupus deforming arthropathy were more frequently positive for rheumatoid factor (65%) than patients with non-deforming arthritis (15%) (p = 0.005). Patients with lupus deforming arthropathy had similar frequency of erosions and mean Sharp’s score than rhupus patients. Anti-CCP antibodies do not associate with lupus arthropathy, whether deforming, non-deforming or erosive.

Keywords

anti-citrullinated cyclic peptide antibodies deforming arthropathy rheumatoid arthritis systemic lupus erythematosus

Get full access to this article

View all access options for this article.

References

1 Nishimura K Sugiyama D Kogata Y . Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 2007; 146: 797 – 808 .

2 Mediwake R Isenberg DA Schellekens GA van Venrooij WJ . Use of anti-citrullinated peptide and anti-RA33 antibodies in distinguishing erosive arthritis in patients with systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis 2001; 60: 67 – 68 .

3 Chan MT Owen P Dunphy J . Anti-cyclic citrullinated peptide antibodies are associated with erosive arthritis in SLE [abstract]. Arthritis Rheum 2005; 9: S611 .

4 Martinez JB Valero JS Bautista AJ . Erosive arthropathy: clinical variance in lupus erythematosus and association with anti-CCP case series and review of the literature. Clin Exp Rheumatol 2007; 25: 47 – 53 .

5 Tan EM Cohen AS Fries JF . The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271 – 1277 .

6 Alarcon-Segovia D Abud-Mendoza C Díaz-Jouanen E . Deforming arthropathy of the hands in systemic lupus erythematosus. J Rheumatol 1988; 15: 65 – 69 .

7 van Vugt RM Derksen RH Kater L Bijlsma JW . Deforming arthropathy or lupus and rhupus hands in systemic lupus erythematosus. Ann Rheum Dis 1998; 57: 540 – 544 .

8 Arnett FC Edworthy SM Bloch D . The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315 – 324 .

9 Simon JA Granados J Cabiedes J Morales JR Varela JA . Clinical and immunogenetic characterization of Mexican patients with 'rhupus'. Lupus 2002; 11: 287 – 292 .

10.

10 Sharp JT Lidsky MD Collins LC Moreland J . Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalities. Arthritis Rheum 1971; 14: 706 – 720 .

11.

11 Alarcón-Segovia D Villarreal M . Classification and diagnostic criteria for classification of mixed connective tissue disease. In: R Kasukawa T Tojo S Miyawaki , (eds), Mixed Connective Tissue Disease and Antinuclear Antibodies. Amesterdam: Elsevier; 1987. p. 33–40.

12.

12 Bizzaro N Tozzoli R Shoenfeld Y . Are we at a stage to predict autoimmune rheumatic diseases? Arthritis Rheum 2007; 56: 1736 – 1744 .

13.

13 Weinstein A Bordwell B Stone B Tibbetts C Rothfield NF . Antibodies to native DNA and serum complement (C3) levels. Application to diagnosis and classification of systemic lupus erythematosus. Am J Med 1983; 74: 206 – 216 .

14.

14 Fernandez A Quintana G Rondon F . Lupus arthropathy: a case series of patients with rhupus. Clin Rheumatol 2006; 25: 164 – 167 .

15.

15 Amezcua-Guerra LM Springall R Marquez-Velasco R . Presence of antibodies against cyclic citrullinated peptides in patients with 'rhupus': a cross-sectional study. Arthritis Res Ther 2006; 8: R144 .